LENZ Therapeutics (LENZ) Change in Accured Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Change in Accured Expenses data on file, last reported at -$2.1 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 75.87% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 800.77% YoY) and the FY2025 annual result came in at $11.0 million, up 247.12% from the prior year.
• Change in Accured Expenses retreated to -$2.1 million in Q1 2026 per LENZ's latest filing, from $5.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q4 2025 and bottomed at -$7.2 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.2 million (2022), against an average of $605529.4.
• The widest annual swing landed in 2024, when Change in Accured Expenses slumped 4782.43%; it then soared 518.45% in 2025.
• Tracing LENZ's Change in Accured Expenses over 5 years: stood at $453000.0 in 2022, then soared by 256.73% to $1.6 million in 2023, then declined by 19.68% to $1.3 million in 2024, then soared by 287.44% to $5.0 million in 2025, then plunged by 142.04% to -$2.1 million in 2026.
• Per Business Quant, the three latest LENZ Change in Accured Expenses figures stand at -$2.1 million (Q1 2026), $5.0 million (Q4 2025), and $4.5 million (Q3 2025).

Peer Comparison